SCHEMBL2869266

SCHEMBL2869266

Fc1ccc([Mg]I)cc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1656508 0.71 CA1 (0.40)
SCHEMBL13499 0.71
SCHEMBL31048536 0.69 CES2 (0.36)
SCHEMBL14763735 0.69 CA12 (0.38)
SCHEMBL6912177 0.69
SCHEMBL6004069 0.69
SCHEMBL137718 0.69
SCHEMBL20184788 0.67
Hydrochloric Acid SCHEMBL3168096 0.67 CA1 (0.36)
Hydrochloric Acid SCHEMBL5318657 0.67 CA1 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021103327-A1 PREPARATION METHOD FOR APREPITANT INTERMEDIATE IMPURITY 中山奕安泰医药科技有限公司 2021-06-03 WO claimed
CN-110963928-B Preparation method of aprepitant intermediate impurity 中山奕安泰医药科技有限公司 2021-03-23 CN claimed
CN-110963928-A Preparation method of aprepitant intermediate impurity 中山奕安泰医药科技有限公司 2020-04-07 CN claimed
WO-2021103327-A1 PREPARATION METHOD FOR APREPITANT INTERMEDIATE IMPURITY 中山奕安泰医药科技有限公司 2021-06-03 WO disclosed
CN-110963928-B Preparation method of aprepitant intermediate impurity 中山奕安泰医药科技有限公司 2021-03-23 CN disclosed
CN-110963928-A Preparation method of aprepitant intermediate impurity 中山奕安泰医药科技有限公司 2020-04-07 CN disclosed
CN-105294496-A Preparation method of citalopram intermediate UNIV SUN YAT SEN 2016-02-03 CN disclosed
WO-2010004575-A2 PREPARATION OF ESCITALOPRAM, ITS SALTS AND INTERMEDIATES SHODHANA LABORATORIES LIMITED (IN) 2010-01-14 WO disclosed
CN-1182125-C Process for synthesis of (2R,2-alpha-R,3a)-2-[1-(3,5-bis(trifluoromethyl)phenyl) ethoxy]-3-(4-fluophenyl)-1,4-oxazine 2004-12-29 CN disclosed
CN-1436178-A Synthesis method of (2R, 2-alpha-R, 3a) -2- [ 1- (3, 5-bis (trifluoromethyl) phenyl) ethoxy ] -3- (4-fluorophenyl) -1, 4-oxazine MERCK & CO INC (US) 2003-08-13 CN disclosed
US-6600040-B2 Reacting 2-alpha-R)-4-benzyl-2-(1-(3,5-bis(trifluoromethyl)phenyl)ethox y-1, 4-oxazin-3-one with a 4-fluorophenyl organometallic reagent in first solvent followed by hydrogentation solvent MERCK & CO., INC. 2003-07-29 US disclosed
EP-1292584-A1 PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3A)-2- 1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-3-(4-FLUOROPHENYL)-1,4-OXAZINE Merck & Co., Inc. (US) 2003-03-19 EP disclosed
US-20020052494-A1 Process for the syntehesis of (2R, 2-alpha-R, 3A) - 2- [1- (3, 5-bis(trifluoromethyl) phenyl) ethoxy] -3- (4-fluorophenyl) -1, 4-oxazine MERCK & CO., INC. 2002-05-02 US disclosed
WO-2001094324-A1 PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3A)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-3-(4-FLUOROPHENYL)-1,4-OXAZINE MERCK & CO., INC. (US) 2001-12-13 WO disclosed